You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR DECITABINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for decitabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed National Heart, Lung, and Blood Institute (NHLBI) 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed Thalassemia Clinical Research Network 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed HealthCore-NERI 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 ↗ Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed New England Research Institutes 2000-07-01 The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00002831 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Completed National Cancer Institute (NCI) Phase 1/Phase 2 1995-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Completed M.D. Anderson Cancer Center Phase 1/Phase 2 1995-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002832 ↗ Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 1/Phase 2 1995-08-01 RATIONALE: Peripheral stem cell transplantation may be an effective treatment for leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia that has relapsed following bone marrow transplantation. PURPOSE: Phase I/II trial to study the effectiveness of decitabine and peripheral stem cell transplantation in treating patients who have leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia that has relapsed after bone marrow transplantation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for decitabine

Condition Name

Condition Name for decitabine
Intervention Trials
Acute Myeloid Leukemia 102
Myelodysplastic Syndromes 62
Myelodysplastic Syndrome 57
Chronic Myelomonocytic Leukemia 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for decitabine
Intervention Trials
Leukemia 215
Leukemia, Myeloid, Acute 201
Leukemia, Myeloid 191
Myelodysplastic Syndromes 166
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for decitabine

Trials by Country

Trials by Country for decitabine
Location Trials
China 96
Canada 56
Germany 50
Italy 44
Australia 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for decitabine
Location Trials
Texas 117
New York 79
California 63
Ohio 60
Maryland 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for decitabine

Clinical Trial Phase

Clinical Trial Phase for decitabine
Clinical Trial Phase Trials
Phase 4 6
Phase 3 39
Phase 2/Phase 3 15
[disabled in preview] 379
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for decitabine
Clinical Trial Phase Trials
Completed 140
Recruiting 107
Not yet recruiting 60
[disabled in preview] 136
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for decitabine

Sponsor Name

Sponsor Name for decitabine
Sponsor Trials
National Cancer Institute (NCI) 99
M.D. Anderson Cancer Center 54
Eisai Inc. 32
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for decitabine
Sponsor Trials
Other 473
Industry 234
NIH 109
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.